Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the Best Small-Cap Growth Stocks to Invest In Now. ​Recently, on June 4, Citizens reiterated a Market Outperform rating on the stock with a price target of $10. The rating comes after the company presented new clinical data at the ASCO conference.

​The data was regarding the company’s CTX-8371, which is a bispecific antibody that targets both PD-1 and PD-L1. PD-1 and PD-L1 are two related immune checkpoint proteins commonly targeted in cancer immunotherapy. The data showed that CTX-8371 showed early signs of activity in heavily pretreated patients across three difficult cancer types, including non-small cell lung cancer, triple-negative breast cancer, and classical Hodgkin lymphoma.

Looking ahead, several catalysts are expected for the stock. For instance, the company plans to meet with the FDA in August to discuss a path toward approval for a separate drug, Tovecimig. Additionally, updated CTX-8371 data and initial results from another candidate, CTX-10726, are both expected later in 2026.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biotechnology company developing antibody-based treatments for cancer.

While we acknowledge the risk and potential of CMPX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1